• Tonix Pharmaceuticals sued Dr. Reddy's Laboratories for patent infringement on November 13, 2026, in New Jersey federal court.
• The lawsuit triggers a stay of final FDA approval for the generic TONMYA application for up to 30 months, subject to exceptions.
• An October 1, 2026, notice disclosed Dr. Reddy's application for generic TONMYA 2.8 mg sublingual tablets, challenging four listed patents.
• The lawsuit seeks to block FDA approval until the last asserted patent expires.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051693), on November 13, 2026, and is solely responsible for the information contained therein.